This is a working overview of ACTH(4–10), written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-08 and is reviewed periodically as new material appears.
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定，遇到强碱或长时间高温则明显断裂；甲硫氨酸侧链容易被氧化成亚砜，使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间，配制后的水溶液通常需要冷藏并尽快用完。
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C37H51N9O10S | 游离碱形式 |
| 等电点 | 约 6.5 | 估算值，随缓冲体系变化 |
| 主要降解途径 | 水解与氧化 | 侧链氧化最为常见 |
| 溶液储存 | 2 至 8 摄氏度避光 | 避免反复冻融 |
| 常规分析手段 | 反相色谱与质谱联用 | 氨基酸分析辅助核对 |
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Pharming, a portmanteau of farming and pharmaceutical, refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming, or biopharming. The products of pharming are recombinant proteins or their metabolic products. Recombinant proteins are most commonly produced using bacteria or yeast in a bioreactor, but pharming offers the advantage to the producer that it does not require expensive infrastructure, and production capacity can be quickly scaled to meet demand, at greatly reduced cost.
Solanine is a glycoalkaloid poison found in species of the nightshade family within the genus Solanum, such as the potato (Solanum tuberosum). It can occur naturally in any part of the plant, including the leaves, fruit, and tubers. Solanine has pesticidal properties, and it is one of the plant's natural defenses. Solanine was first isolated in 1820 from the berries of the European black nightshade (Solanum nigrum), after which it was named. It belongs to the chemical family of saponins.
Newsom campaigned on reducing the cost of health care and increasing access. He also indicated his support for creating a universal state health-care system. The budget passed in June 2019 expanded eligibility for Medi-Cal from solely undocumented minor children to undocumented young adults from ages 19 to 25. In 2021, Newsom signed legislation expanding Medi-Cal eligibility to undocumented residents over age 50. On June 30, 2022, he signed a $307.9 billion state budget that "pledges to make all low-income adults eligible for the state's Medicaid program by 2024 regardless of their immigration status." This budget would make California the first U.S. state to guarantee healthcare to all low-income undocumented immigrants, at a cost of $2.7 billion per year. Newsom was criticized in early 2022 for walking back from his support for universal health care and not supporting CalCare, Assembly Bill 1400, which would have instituted single-payer healthcare in California; critics suggested that opposition from business interests, which had donated large sums to Newsom and his party, had swayed his opinion. On July 6, 2022, Newsom signed Senate Bill 184, which established the Office of Health Care Affordability, with the stated goal to "develop data-informed policies and enforceable cost targets, with the ultimate goal of containing health care costs". In August 2022, Newsom vetoed Senate Bill 57 which sought to authorize jurisdictions to approve supervised injection sites. Newsom signed The Zacky Bill. In October 2023, Newsom vetoed a bill to cap co-pays for insulin at $35.
== Clinical significance == LPS exposure induces LBP production. LBP is synthesized by the liver, adipose tissue, and intestinal cells. Dietary glucose and saturated fats acutely increase plasma LBP. The proinflammatory activity of plasma LPS is increased by LBP, which is higher in obesity. Plasma LBP is used as a better biomarker of plasma LPS than LPS itself due to the short half-life of LPS.
Sources: en.wikipedia.org
In Normandy, the 82nd gained its first Medal of Honor of the war, belonging to Private first class Charles N. DeGlopper of the 325th GIR. When the division was relieved in early July, the 82nd had seen a month straight of severe combat. Casualties were heavy. Losses included 5,245 troopers killed, wounded, or missing- a 46% casualty rate. Major General Ridgway's post-battle report stated in part, "... 33 days of action without relief, without replacements. Every mission accomplished. No ground gained was ever relinquished." Following Normandy, the 82nd Airborne Division returned to England to rest and refit for future airborne operations. The 82nd became part of the newly organized XVIII Airborne Corps, which consisted of the 17th, 82nd, and 101st Airborne Divisions. Ridgway was given command of the corps but was not officially promoted to lieutenant general until 1945. His recommendation for succession as division commander was Brigadier General James M. Gavin, previously the 82nd's assistant division commander. Upon being promoted to major general in October 1944 at the age of 37, Gavin became the youngest general since the Civil War to command a US Army division.
The UCIL factory was built in 1969 to produce the pesticide Sevin (UCC's brand name for carbaryl) using methyl isocyanate (MIC) as an intermediate. An MIC production plant was added to the UCIL site in 1979. The chemical process employed in the Bhopal plant had methylamine reacting with phosgene to form MIC, which was in turn reacted with 1-naphthol to form the final product, carbaryl. Another manufacturer, Bayer, also used this MIC-intermediate process at the chemical plant once owned by UCC at Institute, West Virginia in the United States. After the Bhopal plant was built, other manufacturers (including Bayer) produced carbaryl without MIC, though at a greater manufacturing cost. UCIL's process differed from the MIC-free routes used elsewhere, in which the same raw materials were combined in a different manufacturing order, with phosgene initially reacting with 1-naphthol to form a chloroformate ester, which was later reacted with methylamine. In the early 1980s, although the demand for pesticides had fallen, production continued leading to an accumulation of unused MIC at the Bhopal site.
==== Elimination ==== More than 55% of THC is excreted in the feces and approximately 20% in the urine. The main metabolite in urine is the ester of glucuronic acid and 11-OH-THC and free THC-COOH. In the feces, mainly 11-OH-THC was detected. Estimates of the elimination half-life of THC are variable. THC was reported to have a fast initial half-life of 6 minutes and a long terminal half-life of 22 hours in a population pharmacokinetic study. Conversely, the Food and Drug Administration label for dronabinol reports an initial half-life of 4 hours and a terminal half-life of 25 to 36 hours. Many studies report an elimination half-life of THC in the range of 20 to 30 hours. 11-Hydroxy-THC appears to have a similar terminal half-life to that of THC, for instance 12 to 36 hours relative to 25 to 36 hours in one study. The elimination half-life of THC is longer in heavy users. This may be due to slow redistribution from deep compartments such as fatty tissues, where THC accumulates with regular use.
Sources: en.wikipedia.org
电喷雾或基质辅助激光解吸电离质谱是常用手段，测得的质子化离子质荷比可换算为分子量。结果与理论值落在合理误差内，才支持结构一致的判断。
甲硫氨酸侧链含硫醚，在氧气、光照或金属离子存在时容易被氧化。氧化产物极性略增，常在色谱图上表现为主峰之前的肩峰或前伸峰。
通常建议冷藏避光，并在较短时间内使用。不存在适用于所有配方的统一期限，具体取决于浓度、缓冲体系与容器材质。
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.